New treatment for tendon deterioration using exosomes
Exosome drug for tendinopathy
This study is testing a new treatment called Altenex, which uses tiny particles from human stem cells to help heal painful tendon injuries and improve how they work, giving hope to people with tendinopathy.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York/r&d/ctr/translational Med/ther NIH-funded |
| Lab location | 1 site (New Rochelle, UNITED STATES) |
| Project ID | NIH-10921023 on NIH RePORTER |
What this research studies
This research focuses on developing a novel biologic drug called Altenex, which utilizes exosomes derived from human bone marrow stem cells to treat tendinopathy, a painful condition affecting tendons. The approach involves culturing these stem cells on specialized 3D scaffolds that mimic the natural environment of tendons, promoting the production of therapeutic exosomes. By injecting these exosomes directly into affected tendons, the goal is to reduce pain and improve tendon healing and function. This innovative method aims to provide a disease-modifying treatment where none currently exists.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing chronic tendinopathy, particularly those with pain and functional impairment in their tendons.
Not a fit: Patients with acute tendon injuries or those who do not have a diagnosis of tendinopathy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a safe and effective treatment option for patients suffering from tendinopathy, potentially improving their quality of life and physical performance.
How similar studies have performed: Other research has shown promise in using stem cell-derived exosomes for tissue repair, indicating that this approach may be effective for treating tendinopathy as well.
Where this research is happening
New Rochelle, UNITED STATES
- New York/r&d/ctr/translational Med/ther — New Rochelle, United States (Active)
Researchers
- Principal investigator: Fung, David T — New York/r&d/ctr/translational Med/ther
- Study coordinator: Fung, David T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.